(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.23%) $79.13
(-0.98%) $2.02
(0.01%) $2 309.80
(0.19%) $26.88
(0.34%) $965.90
(-0.06%) $0.932
(-0.10%) $10.98
(-0.14%) $0.797
(1.51%) $92.51
Live Chart Being Loaded With Signals
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer...
Stats | |
---|---|
Dagens volum | 1.25M |
Gjennomsnittsvolum | 126 338 |
Markedsverdi | 20.90M |
EPS | $0 ( 2024-04-04 ) |
Neste inntjeningsdato | ( $-0.230 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.040 |
ATR14 | $0.0140 (1.42%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-13 | Guerin Mark Patrick | Buy | 8 666 | Common Stock |
2024-03-14 | Guerin Mark Patrick | Sell | 2 591 | Common Stock |
2024-03-13 | Guerin Mark Patrick | Sell | 8 666 | Restricted Stock Units |
2024-03-13 | Fruchtman Steven M | Buy | 23 111 | Common Stock |
2024-03-14 | Fruchtman Steven M | Sell | 8 727 | Common Stock |
INSIDER POWER |
---|
75.80 |
Last 95 transactions |
Buy: 2 889 396 | Sell: 191 603 |
Volum Korrelasjon
Onconova Therapeutics Inc Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Onconova Therapeutics Inc Korrelasjon - Valuta/Råvare
Onconova Therapeutics Inc Økonomi
Annual | 2023 |
Omsetning: | $226 000 |
Bruttogevinst: | $226.00B (100 000 000.00 %) |
EPS: | $-0.900 |
FY | 2023 |
Omsetning: | $226 000 |
Bruttogevinst: | $226.00B (100 000 000.00 %) |
EPS: | $-0.900 |
FY | 2022 |
Omsetning: | $226 000 |
Bruttogevinst: | $212 000 (93.81 %) |
EPS: | $-0.880 |
FY | 2021 |
Omsetning: | $226 000 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-0.960 |
Financial Reports:
No articles found.
Onconova Therapeutics Inc
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.